BLUE vs. SGMO, GRTS, OTLK, LIFE, OMGA, VIGL, PASG, CRIS, DBVT, and ALVR
Should you be buying bluebird bio stock or one of its competitors? The main competitors of bluebird bio include Sangamo Therapeutics (SGMO), Gritstone bio (GRTS), Outlook Therapeutics (OTLK), aTyr Pharma (LIFE), Omega Therapeutics (OMGA), Vigil Neuroscience (VIGL), Passage Bio (PASG), Curis (CRIS), DBV Technologies (DBVT), and AlloVir (ALVR). These companies are all part of the "biological products, except diagnostic" industry.
Sangamo Therapeutics (NASDAQ:SGMO) and bluebird bio (NASDAQ:BLUE) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, community ranking, dividends, valuation, analyst recommendations, profitability, media sentiment and risk.
56.9% of Sangamo Therapeutics shares are owned by institutional investors. Comparatively, 87.4% of bluebird bio shares are owned by institutional investors. 2.8% of Sangamo Therapeutics shares are owned by insiders. Comparatively, 2.1% of bluebird bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Sangamo Therapeutics presently has a consensus price target of $5.67, indicating a potential upside of 830.95%. bluebird bio has a consensus price target of $5.74, indicating a potential upside of 447.09%. Given bluebird bio's stronger consensus rating and higher possible upside, equities analysts plainly believe Sangamo Therapeutics is more favorable than bluebird bio.
In the previous week, bluebird bio had 3 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 14 mentions for bluebird bio and 11 mentions for Sangamo Therapeutics. Sangamo Therapeutics' average media sentiment score of 0.12 beat bluebird bio's score of -0.03 indicating that bluebird bio is being referred to more favorably in the news media.
bluebird bio received 596 more outperform votes than Sangamo Therapeutics when rated by MarketBeat users. Likewise, 71.78% of users gave bluebird bio an outperform vote while only 62.71% of users gave Sangamo Therapeutics an outperform vote.
Sangamo Therapeutics has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500. Comparatively, bluebird bio has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500.
Sangamo Therapeutics has higher revenue and earnings than bluebird bio. bluebird bio is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.
bluebird bio has a net margin of -419.64% compared to bluebird bio's net margin of -1,749.06%. Sangamo Therapeutics' return on equity of -34.32% beat bluebird bio's return on equity.
Summary
bluebird bio beats Sangamo Therapeutics on 11 of the 18 factors compared between the two stocks.
Get bluebird bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for BLUE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BLUE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
bluebird bio Competitors List
Related Companies and Tools
